Tonix Pharmaceuticals Holding Corp. ã¯ãããã®ç
æ°ãæ²»çããã³äºé²ããèŠçã軜æžããããã®äœååããã³çç©è£œå€ãçºèŠãååŸãéçºãã©ã€ã»ã³ã¹äŸäžããŠããŸããå
ç«åŠã®è£œååè£ã«ã¯ãææçãäºé²ããããã®ã¯ã¯ãã³ããå
ç«æå¶ããããèªå·±å
ç«çŸæ£ã«å¯ŸåŠããããã®çç©è£œå€ãå«ãŸããäžæ¢ç¥çµç³» (CNS) ã®è£œååè£ã«ã¯ãçã¿ãç¥çµã粟ç¥ãäŸåçã®çç¶ãæ²»çããããã®äœååããã³çç©è£œå€ãå«ãŸããŸããå瀟ã®äž»åã¯ã¯ãã³åè£ã¯ãCOVID-19 ãäºé²ããããã®éЬçãŠã€ã«ã¹ãã¯ã¿ãŒãã©ãããã©ãŒã ã«åºã¥ãçè€è£œã¯ã¯ãã³ã§ãã TNX-1800 ã§ããå瀟ã®ã¯ã¯ãã³ã«ã¯ã倩ç¶çããµã«çãäºé²ãããã¯ã¿ãŒãã©ãããã©ãŒã ãšããŠæ©èœããç銬çãŠã€ã«ã¹ã¯ã¯ãã³ã§ãã TNX-801 ããCOVID-19 ã®äºé²ã®ããã® TNX-2300 ãå«ãŸããŠããŸããå瀟ã®äž»å CNS åè£è¬ã¯ãç·ç¶çççãã¢ã«ããã€ããŒç
ãå¿çå€å·åŸã¹ãã¬ã¹é害 (PTSD)ãã¢ã«ã³ãŒã«äœ¿çšé害ã«ãããèå¥®ã®æ²»çè¬ã§ããã·ã¯ããã³ã¶ããªã³ã®èäžé è£œå€ TNX-102 SL ã§ããå瀟ã®è£œåã«ã¯ãã³ã«ã€ã³äžæ¯æ²»çè¬ TNX-1300ããã€ç
ãPTSDãã³ã«ãã³ã¹ããã€ãã«ããç¥çµèªç¥éå®³ã®æ²»çè¬ TNX-601 CRãçé çããã³é èé¡é¢çã®æ²»çè¬ TNX-1900 ãªã©ããããŸããåèšåºãã€ãã©ã€ã³ã«ã¯ãPTSDããã€ç
ãæ³šææ¬ é¥å€åæ§éå®³ã®æ²»çè¬ TNX-1600ãèããããã³èµèããã®æ²»çè¬ TNX-1700ãæŸå°ç·é²è·çšã® TNX-701ã倩ç¶çã¯ã¯ãã³ TNX-1200 ãªã©ããããŸããå瀟ã¯ãèåšç§»æ€æçµ¶åå¿èªå·±å
ç«ã«å¯Ÿããã¢ãã¯ããŒãã«æäœæCD40-Lã®TNX-1500ãããã³ãã©ããŒã»ãŠã£ãªãŒçåçŸ€ã®æ²»çã®ããã®éŒ»è
å
å¢åŒ·ãªãã·ãã·ã³ã®TNX-2900ãéçºããŠããããŸããCOVID-19ç®èæ€æ»ã®TNX-2100ãéçºããŠãããå瀟ã¯ãµã¶ã³ç ç©¶æãã³ãã³ãã¢å€§åŠãã¢ã«ããŒã¿å€§åŠãããµãã¥ãŒã»ããç·åç
é¢ãšåååå®ãçµãã§ãããå瀟ã¯2007幎ã«èšç«ããããã¥ãŒãžã£ãŒãžãŒå·ãã£ã¿ã ã«æ¬ç€Ÿã眮ããŠããã